Xintela AB (publ) (XINT.ST)
SEK 0.32
(-0.63%)
SEK 0.32
(-0.63%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 398 Thousand SEK | 24.76% |
| 2022 | 319 Thousand SEK | -54.82% |
| 2021 | 706 Thousand SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -2.22 Million SEK | -205.08% |
| 2017 | -728 Thousand SEK | -32.36% |
| 2016 | -550 Thousand SEK | 40.28% |
| 2015 | -921 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | -4.07 Million SEK | 0.0% |
| 2024 Q1 | - SEK | -100.0% |
| 2023 Q4 | 398 Thousand SEK | 0.0% |
| 2023 Q2 | 1.19 Million SEK | 0.0% |
| 2023 Q3 | - SEK | -100.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 FY | 398 Thousand SEK | 24.76% |
| 2022 Q2 | -4.12 Million SEK | 16.81% |
| 2022 Q4 | 319 Thousand SEK | 106.32% |
| 2022 FY | 319 Thousand SEK | -54.82% |
| 2022 Q1 | -4.95 Million SEK | -801.98% |
| 2022 Q3 | -5.04 Million SEK | -22.36% |
| 2021 Q2 | 683 Thousand SEK | -41.67% |
| 2021 Q3 | 683 Thousand SEK | 0.0% |
| 2021 Q4 | 706 Thousand SEK | 3.37% |
| 2021 FY | 706 Thousand SEK | 0.0% |
| 2021 Q1 | 1.17 Million SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | -2.22 Million SEK | -205.08% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q1 | 1.00 SEK | 0.0% |
| 2018 Q2 | - SEK | -100.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | -728 Thousand SEK | -32.36% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 FY | -550 Thousand SEK | 40.28% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 100.0% |
| 2015 FY | -921 Thousand SEK | 0.0% |
| 2015 Q4 | -277 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -19899900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 109.501% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 105.577% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 97.33% |
| Intervacc AB (publ) | 10.48 Million SEK | 96.203% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 16020.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 98.87% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 95.611% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 20510.256% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 87.365% |
| Saniona AB (publ) | 1.00 SEK | -39799900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 124.477% |
| Biovica International AB (publ) | 2.19 Million SEK | 81.901% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -39799900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 80.865% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 43.143% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 146.118% |
| Amniotics AB (publ) | 534 Thousand SEK | 25.468% |
| 2cureX AB (publ) | -1000.00 SEK | 39900.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 122.123% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 98.052% |
| Camurus AB (publ) | 100.95 Million SEK | 99.606% |
| Corline Biomedical AB | -3.85 Million SEK | 110.319% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -39700.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | 90.701% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 95.935% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 108.075% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 27.004% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 99.091% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 189.041% |
| Nanologica AB (publ) | 2.97 Million SEK | 86.613% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 223.932% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 96.64% |
| Alzinova AB (publ) | -3.27 Million SEK | 112.142% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 83.588% |
| Pila Pharma AB (publ) | 1.00 SEK | -39799900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 26883.311% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 90.134% |
| Simris Alg AB (publ) | 1.09 Million SEK | 63.52% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 98.345% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 99.628% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 61.284% |